ERBB2 and non-small cell lung carcinoma: The DESTINY-Lung01 study demonstrated an overall response rate (ORR) of 55.4%, and the findings from DESTINY-Lung02 further corroborated these positive results, with similar ORRs reported for patients with HER2 mutations in NSCLC.